What are the new drugs for Thyroid Cancer?
New multikinase inhibitors and targeted therapies are now approved and under investigation for advanced or radioiodine‑refractory thyroid cancers, offering improved progression‑free survival and expanding treatment options.
This article reviews the landscape of newly approved and investigational targeted therapies and immunotherapies for differentiated, poorly differentiated, anaplastic, and medullary thyroid carcinoma, emphasizing multikinase inhibitors, BRAF/RET‑selective agents, NTRK inhibitors, and checkpoint inhibitors, and their impact on progression‑free survival.
These therapies provide new treatment options with improved progression‑free survival for patients with advanced or RAI‑refractory thyroid cancer, addressing unmet clinical needs.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management